The Taimet Merger Review

Not every merger is a competitive threat, as this episode of the Taimet Merger Review points out. GSK/Nuvalent's Taimet Score was 17, putting it firmly in early termination territory. This episode walks through why. First and most importantly, GSK is acquiring a smaller oncology company whose pipeline drugs target a narrowly defined biomarker-driven lung cancer market where GSK has no existing presence. With no product market overlaps, unchanged HHIs, and no vertical links, and no history of antitrust complaints from either party. And pro-competitive effects that are hard to argue with: faster market entry for drugs still clearing FDA hurdles, and the manufacturing scale to bring them there. The episode also discusses the pharmaceutical-specific analytical framework. It covers why firm size matters when evaluating pharma acquisitions, how to think about the industry consolidation trend when the relevant product markets are distinct, and what it actually means for a large company to enter a narrowly defined market through acquisition rather than independent development. A useful counterpoint episode for anyone who wants to see how the analysis looks when the answer isn't remedies or litigation. It's also a good illustration of how Taimet handles pharmaceutical transactions specifically. Learn more about Taimet at https://www.taimet.com

United Airlines' reported bid to acquire American Airlines drew immediate scrutiny and collapsed within weeks - but the competitive analysis tells a deeper story. This episode walks through Taimet's analysis of the transaction, which scored a 79 out of 100 - squarely in remedies territory - and layers in Gwendolyn's enforcement experience to explain why. Topics include the nationwide network carrier cluster market and what it means for corporate travel purchasers, illustrative city pair overlaps out of the 380 Taimet identified (including duopoly-to-monopoly routes through Chicago O'Hare and Reagan National), merger guideline implications from coordination risk to labor monopsony, the political overlay, and why state attorneys general may pose the biggest obstacle of all for any future attempt at this deal. Whether you're an investor assessing regulatory risk, an enforcer thinking about triage, or just someone who wants to understand how antitrust analysis actually works on a real transaction, this episode is a good place to start. Learn more about Taimet at https://www.taimet.com

Gwendolyn Lindsay Cooley introduces The Taimet Merger Review - a monthly deep dive into the antitrust risk of a single merger. Each episode walks through a Taimet analysis of a real deal: the market overlaps, the competitive structure, and the enforcement theories that actually matter. Then Gwendolyn pressure-tests it - where she agrees with the analysis, where she pushes back, and what her two decades of enforcement experience add to the picture. Built for investors, advisors, deal teams, and anyone who needs to understand whether a merger clears or attracts scrutiny - and why. New episodes monthly. The Taimet Merger Review is produced by Taimet, the first AI platform purpose-built for merger antitrust risk analysis. Learn more at www.taimet.com.